ENLV Stock — Enlivex Ltd.: Cash, EV, Pipeline

Share price

$0.81

Market cap

$14.1M

Cash

$5.8M

Enterprise value

$8.3M

Balance sheet

Cash	$5.8M
Debt	$0.0M
Net cash	$5.8M
Enterprise value	$8.3M
Basic shares	17.4M shares
Fully diluted shares	18.0M shares
Fully diluted market cap	$14.6M
Cash per share	$0.33

Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.

Price history

Loading ENLV daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Mar 15 - Apr 26	Allocetra	Phase 2	Primary Knee Osteoarthritis	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Allocetra

Stage not disclosed · Active Modality: universal, off-the-shelf cell therapy

Target Macrophages (reprogramming to homeostatic state)

Indications

Osteoarthritis (Stage not disclosed)
Sepsis (Stage not disclosed)

Status note Clinical-stage company but excerpts do not state the current trial phase for Allocetra. Company plans to seek external collaboration or out-licensing for continued sepsis development rather than pursuing it internally.

Per-asset detail extracted from the 20-F filed 2026-03-25. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Allocetra
Lead indication	Primary Knee Osteoarthritis
Lead phase	Phase 2
Active trials	2
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07580716	Phase 2	Recruiting	Sponsor	ENLV	—	Primary Knee Osteoarthritis	—
NCT06233474	Phase 2	Active, not recruiting	Sponsor	ENLV	—	Osteoarthritis, Knee	—
NCT06208241	Early Phase 1	Active, not recruiting	Collaborator	Amir Oron	—	Knee Osteoarthritis	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Enlivex Therapeutics Ltd. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ENLV — Enlivex Ltd.